Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc) Meeting Abstract
| Authors: | Gutierrez, M.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; Garon, E.; Finocchiaro, G.; Ahn, M. J.; Luft, A.; Landers, G.; Basso, A.; Ma, H.; Kobie, J.; Palcza, J.; Cristescu, R.; Fong, L.; Snyder, A.; Yuan, J.; Herbst, R. |
| Abstract Title: | Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc) |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A485 |
| Language: | English |
| ACCESSION: | WOS:000774877500439 |
| DOI: | 10.1136/jitc-2021-SITC2021.457 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 457 -- Meeting was also presented virtually -- Source: Wos |
